Clinical Trial: Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT03912909) titled 'Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans' on Oct. 23, 2018.

Brief Summary: This study is designed to investigate whether the sodium-glucose co-transporter-2 (SGLT-2) inhibitor Empagliflozin reduces sympathetic nervous system (SNS) activity in humans.

Study Type: Interventional

Condition: * Metabolic Syndrome

* Type 2 Diabetes Mellitus

* Obesity

Intervention: * Drug: Empagliflozin Oral Tablet [Jardiance]

Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study ...